Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials

Wang, 2022, Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019, Front Public Health, 10 Siegel, 2023, Cancer statistics, 2023, CA Cancer J Clin, 73, 17, 10.3322/caac.21763 Bill-Axelson, 2018, Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up, N Engl J Med, 379, 2319, 10.1056/NEJMoa1807801 Choi, 2019, Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: the Korean Cancer Study of the Prostate risk classification, Int J Urol, 26, 62, 10.1111/iju.13800 Schroder, 2012, Androgen deprivation therapy: past, present and future, BJU Int, 109, 1, 10.1111/j.1464-410X.2012.11215.x Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396 de Freitas, 2019, Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries, Adv Ther, 36, 318, 10.1007/s12325-018-0861-3 Fizazi, 2022, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design, Lancet, 399, 1695, 10.1016/S0140-6736(22)00367-1 Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115 Pan, 2022, Olaparib outcomes in metastatic castration-resistant prostate cancer: first real-world experience in safety and efficacy from the Chinese mainland, Prostate Int, 10, 142, 10.1016/j.prnil.2022.04.005 Kim, 2022, A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways, Prostate Int, 11, 83, 10.1016/j.prnil.2022.11.003 Woods, 2010, Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial, BMC Med Res Methodol, 10, 54, 10.1186/1471-2288-10-54 Akaza, 2009, Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival, Cancer, 115, 3437, 10.1002/cncr.24395 Usami, 2007, Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients, Prostate Cancer Prostatic Dis, 10, 194, 10.1038/sj.pcan.4500934 Tyrrell, 2000, Comparison of an LH-RH analogue (Goeserelin acetate, ‘Zoladex’) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group, Eur Urol, 37, 205, 10.1159/000020119 Schellhammer, 1997, Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group, Urology, 50, 330, 10.1016/S0090-4295(97)00279-3 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1036, 10.1056/NEJM199810083391504 de Reijke, 2002, Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update, Eur Urol, 42, 139, 10.1016/S0302-2838(02)00272-5 Palmbos, 2021, A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer, Clin Cancer Res, 27, 3017, 10.1158/1078-0432.CCR-21-0024 Alghandour, 2021, Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED), Urol Oncol, 39, 10.1016/j.urolonc.2021.05.020 Armstrong, 2022, Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 40, 1616, 10.1200/JCO.22.00193 Vaishampayan, 2021, Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2020.34633 Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8 Gu, 2022, Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial, Lancet Oncol, 23, 1249, 10.1016/S1470-2045(22)00507-1 Chi, 2021, Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study, J Clin Oncol, 39, 2294, 10.1200/JCO.20.03488 Agarwal, 2022, Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216), J Clin Oncol, 40, 3301, 10.1200/JCO.21.02517 James, 2022, Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476), Int J Cancer, 151, 422, 10.1002/ijc.34018 Mori, 2022, Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis, BJU Int, 129, 423, 10.1111/bju.15507 Wang, 2021, Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis, JAMA Oncol, 7, 412, 10.1001/jamaoncol.2020.6973 Boyle, 2019, Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients, Eur J Cancer, 116, 116, 10.1016/j.ejca.2019.04.031 Mandel, 2023, Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis, Eur Urol Focus, 9, 96, 10.1016/j.euf.2022.08.007 Clegg, 2012, ARN-509: a novel antiandrogen for prostate cancer treatment, Cancer Res, 72, 1494, 10.1158/0008-5472.CAN-11-3948 Hussain, 2023, Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial, J Clin Oncol